This trial is active, not recruiting.

Condition ovarian cancer
Treatment exercise
Phase phase 0
Sponsor Abramson Cancer Center of the University of Pennsylvania
Start date May 2015
End date December 2015
Trial size 10 participants
Trial identifier NCT02529150, UPCC 38814


One in four deaths in the United States is due to cancer, and one in three women will develop cancer in her lifetime. Despite improvements in survival among other forms of cancer, ovarian cancer prognosis remains poor. Eighty percent of women with ovarian cancer will present with advanced disease (stage 3 or 4) where 5-year survival ranges from 18-34%.2 Among patients with stage III and IV epithelial ovarian cancer (EOC), recurrence rates are high.4 Therefore, interventions focused on preventing recurrence or slowing progression of EOC is a critical problem in the field. The investigators have submitted an R21 to NCI for a dose response exercise intervention trial to examine the dose response effects of aerobic exercise on biomarkers relevant to ovarian cancer progression and recurrence. The reviewers would like assurance that the investigators can recruit ovarian cancer patients into an exercise study and that these women will do the exercise protocol we plan to prescribe in our high dose of exercise.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Primary purpose supportive care

Primary Outcomes

Number of adverse events
time frame: 26 weeks

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of stage III-IV EOC, completed surgery, - > 12 months life expectancy (physician estimate), - able to walk 15 minutes at a time (use of a cane is acceptable). Exclusion Criteria: - medical or psychiatric conditions (beyond ovarian cancer, its treatment, and its symptoms) that would impair our ability to test study hypotheses (e.g. cardiac, pulmonary, or - orthopedic history that would prohibit a program of walking for exercise; - psychotic disorders, - dementia, - inability to give informed consent

Additional Information

Official title WISER After Ovarian Cancer - Exercise Pilot Study
Principal investigator Kathryn Schmitz, PhD
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Abramson Cancer Center of the University of Pennsylvania.